- Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
-
Murakami M, Fujimaki T, Asano S, Nakaguchi , Yamada SM, Hoya K, Yamazaki K, Ishida Y, Matsuno A
- KMID: 1058828
- Yonsei Med J.
- 2011 Nov;52(6):1031-1034.
- doi: 10.3349/ymj.2011.52.6.1031
High-dose methotrexate-based chemotherapy has extended survival in patients with primary central nervous system lymphoma (PCNSL). However, although salvage treatment is necessary in recurrent and refractory PCNSL, this has not been... -
- CITED
-
- Close
- SHARE
-
- Close
- A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue
-
Hong SJ, Kim JS, Chang JH, Kim KM, Kim SJ, Lee HW, Cheong JW, Lee ST, Min YH
- KMID: 2396073
- Yonsei Med J.
- 2009 Apr;50(2):280-283.
The prognosis for patients with primary central nervous system (CNS) lymphoma (PCNSL) who relapse after the initial response is usually poor. A standard treatment for relapsed PCNSL has not yet... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
-
Sung KH, Lee EH, Kim YZ
- KMID: 1777887
- J Korean Med Sci.
- 2011 Apr;26(4):551-560.
- doi: 10.3346/jkms.2011.26.4.551
The authors investigated objective response rate to high dose methotrexate (HDMTX)-based combination chemotherapy in primary central nervous system lymphoma (PCNSL), and sought to identify factors that influence response to HDMTX-based... -
- CITED
-
- Close
- SHARE
-
- Close
